Eurazeo Cash Flow Conversion Efficiency

Latest as of June 2026: -0.021x

Eurazeo cash flow conversion efficiency. Based on the latest financial reports, Eurazeo (RF) has a cash flow conversion efficiency ratio of -0.021x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-133.24 Million ≈ $-155.77 Million USD) by net assets (€6.26 Billion ≈ $7.32 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Eurazeo (2007–2025)

Cash flow conversion efficiency of Eurazeo from 2007 to 2025. This chart illustrates how Eurazeo's cash flow conversion efficiency has evolved over time, based on yearly financial data. View RF share price today for real-time trading data and today's change.

Eurazeo Cash Flow Conversion Ratio Explained

Eurazeo cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Eurazeo Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Eurazeo ranked by their cash flow conversion efficiency. Also see market cap of Eurazeo for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Lepu Medical Tech Beijing
SHE:300003
0.024x
Nien Made Enterprise Co Ltd
TW:8464
0.048x
Alliance Resource Partners LP
NASDAQ:ARLP
0.086x
Aya Gold & Silver Inc
TO:AYA
0.095x
MERCARI INC. UNSP.ADR/1/2
F:6TP0
-0.048x
Community Bank System Inc
NYSE:CBU
0.035x
Freshworks Inc
NASDAQ:FRSH
0.065x
Wendel
PA:MF
0.079x

Annual Cash Flow Conversion Efficiency for Eurazeo (2007–2025)

The table below shows the annual cash flow conversion efficiency of Eurazeo from 2007 to 2025. Review Eurazeo free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 €6.49 Billion
≈ $7.59 Billion
€125.83 Million
≈ $147.11 Million
0.019x +112.36%
2024-12-31 €7.55 Billion
≈ $8.82 Billion
€68.88 Million
≈ $80.53 Million
0.009x +756.90%
2023-12-31 €8.35 Billion
≈ $9.77 Billion
€-11.61 Million
≈ $-13.57 Million
-0.001x -105.07%
2022-12-31 €9.28 Billion
≈ $10.85 Billion
€254.09 Million
≈ $297.06 Million
0.027x -27.64%
2021-12-31 €8.36 Billion
≈ $9.78 Billion
€316.42 Million
≈ $369.93 Million
0.038x +62.94%
2020-12-31 €6.10 Billion
≈ $7.14 Billion
€141.73 Million
≈ $165.70 Million
0.023x -67.95%
2019-12-31 €6.62 Billion
≈ $7.74 Billion
€479.57 Million
≈ $560.67 Million
0.072x +87.67%
2018-12-31 €6.27 Billion
≈ $7.34 Billion
€242.21 Million
≈ $283.16 Million
0.039x +17.85%
2017-12-31 €6.00 Billion
≈ $7.01 Billion
€196.43 Million
≈ $229.65 Million
0.033x +24.57%
2016-12-31 €5.24 Billion
≈ $6.12 Billion
€137.68 Million
≈ $160.96 Million
0.026x +139.10%
2015-12-31 €4.75 Billion
≈ $5.55 Billion
€-319.26 Million
≈ $-373.25 Million
-0.067x -160.77%
2014-12-31 €3.52 Billion
≈ $4.12 Billion
€389.80 Million
≈ $455.71 Million
0.111x -43.18%
2013-12-31 €3.45 Billion
≈ $4.03 Billion
€671.06 Million
≈ $784.54 Million
0.195x -5.75%
2012-12-31 €3.30 Billion
≈ $3.86 Billion
€681.69 Million
≈ $796.97 Million
0.207x -19.25%
2011-12-31 €3.86 Billion
≈ $4.51 Billion
€988.08 Million
≈ $1.16 Billion
0.256x +58.89%
2010-12-31 €3.94 Billion
≈ $4.61 Billion
€634.95 Million
≈ $742.32 Million
0.161x -42.84%
2009-12-31 €3.87 Billion
≈ $4.53 Billion
€1.09 Billion
≈ $1.28 Billion
0.282x +1.11%
2008-12-31 €3.93 Billion
≈ $4.59 Billion
€1.09 Billion
≈ $1.28 Billion
0.279x +124.34%
2007-12-31 €5.43 Billion
≈ $6.35 Billion
€674.61 Million
≈ $788.69 Million
0.124x --

About Eurazeo

PA:RF France Asset Management
Market Cap
$3.78 Billion
€3.23 Billion EUR
Market Cap Rank
#4440 Global
#76 in France
Share Price
€50.75
Change (1 day)
-0.20%
52-Week Range
€37.78 - €57.10
All Time High
€84.15
About

Eurazeo SE is a private equity and venture capital firm specializing in growth capital, series C, acquisitions, leveraged buyouts, and buy-ins of a private company, and investments in upper mid-market, mid-market and listed public companies, small- and mid-cap healthcare companies, equity in the small-mid and mid-large buyout segments. The firm seeks to invest in medium-sized or large companies, … Read more